FATE
Fate Therapeutics Inc

6,249
Loading...
Loading...
News
all
press releases
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·27d ago
News Placeholder
More News
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
Zacks·3mo ago
News Placeholder
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
Zacks·4mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.
Stocktwits·5mo ago
News Placeholder
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Latest Ratings for FATE DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyMaintainsEqual-Weight Dec 2021WedbushUpgradesNeutralOutperform View More Analyst...
Benzinga·1y ago
News Placeholder
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm FATE SHAREHOLDER ALERT: Kaskela...
PR Newswire·1y ago

Latest FATE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.